Exploring immune responses to cell therapy in tumors
Official title: A Prospective Trial to Evaluate Immune Determinants of the Response and the Toxicity to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Run by Gustave Roussy, Cancer Campus, Grand Paris · NCT05481502 · Data updated 2026-11-12
This study is testing how the immune system reacts to a new cell therapy in patients with different types of tumors to see if these reactions can help predict how well the treatment works and what side effects might occur.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 2 Years and up |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris Academic / other |
| Locations | 1 site (Villejuif, Val de Marne) |
| Status | Recruiting |
| Started | June 8, 2022 |
| Main results expected | July 1, 2027 |
| Study ends | July 1, 2027 |
| Registry record updated | November 6, 2026 |
| Trial ID | NCT05481502 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with accessible tumor lesions who are over 2 years old and can provide informed consent.
✕Probably not a fit
Patients with coagulation abnormalities that prevent biopsies or those who are pregnant or nursing may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the immune responses to adoptive cell therapy in patients with solid and hematologic tumors. It focuses on analyzing the phenotypic and transcriptional changes in tumor cells, blood, and bone marrow following treatment. The goal is to correlate these changes with clinical outcomes and side effects, ultimately identifying specific immune profiles that predict responses to therapy.
Why it matters
Potential benefit: If successful, this study could lead to more effective and personalized treatments for patients with various types of cancer.
How similar studies have gone: While similar studies have explored immune responses to cell therapies, this specific approach focusing on phenotypic and transcriptional profiling is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient affiliated to a social security regimen * Tumor lesion accessible to core biopsies * Patient who is fully informed, able to comply with the protocol and who signed the informed consent * Pediatric patients \> than 2 years old can be included * No restriction about the Eastern Cooperative Oncology Group (ECOG) status Exclusion Criteria: * Coagulation abnormality prohibiting a biopsy (but patients can still give their consent for blood and bone marrow samples). * Tumor lesion not accessible to core biopsies. * Pregnant or nursing women cannot participate in this study.
Where it's running
-
Gustave Roussy Cancer Campus Grand Paris
Villejuif, Val de Marne, France Recruiting
Study contacts
- Study coordinator: Camille BIGENWALD, MD
- Email: camille.bigenwald@gustaveroussy.fr
- Phone: +33 (0)1 42 11 42 29
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Using Nivolumab after Half-Matched Bone Marrow Transplant for Sarcoma
This study is testing if a new drug called Nivolumab can help prevent or delay the return of high-risk sarcomas in children and adults after they receive a special type of bone marrow transplant.
-
Virtual reality to improve comfort for adults with hematologic cancer in hospital
Researchers are testing whether short VR experiences can help comfort and mood for adults with blood cancers who are staying in the hospital for at least 15 days.
-
HMPL-A830 in solid tumors for adults with unresectable or metastatic cancer
This first-in-human study tests HMPL-A830 in adults with unresectable or metastatic solid tumors to see how safe it is and how it behaves at varying doses.
-
Genetics of Blood Cancers in the U.S. population
This study tests how genetic factors relate to blood cancers by collecting saliva DNA and online health surveys from at least 10,000 U.S. adults.
-
Imaging with 89Zr-DFO-YS5 to detect cancer
This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.
-
Venetoclax added to reduced-intensity conditioning for combined stem cell and kidney transplant
This trial tests whether adding venetoclax to a reduced-intensity conditioning regimen is safe for adults with blood cancers who are receiving a combined stem cell and kidney transplant from a matched or partially matched donor.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.